Get the Stockscreener App
25.45
0.08%
-0.02
Xoma Corporation stock is traded at $25.45, with a volume of 2,171.
It is down -0.08% in the last 24 hours and up +0.31% over the past month.
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
See More
Previous Close:
$25.47
Open:
$25.4638
24h Volume:
2,171
Relative Volume:
0.35
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.51%
1M Performance:
+0.31%
6M Performance:
-0.23%
1Y Performance:
+0.20%
1-Day Range:
$25.39
$25.49
1-Week Range:
$25.32
$25.49
52-Week Range:
$23.32
$25.76
Xoma Corporation Stock (XOMAO) Company Profile
Name
Xoma Corporation
Sector
Industry
Phone
510 204 7200
Address
2200 Powell Street, Suite 310, EmeryVille
Compare XOMAO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMAO
Xoma Corporation
|
25.39 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.43 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.34 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
746.53 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.62 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xoma Corporation Stock (XOMAO) Latest News
Layoff Watch: Why is XOMA Royalty Corporation stock going downJuly 2025 WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
Responsive Playbooks and the XOMAP Inflection - Stock Traders Daily
XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Update - MarketBeat
XOMA: Diversified royalty portfolio, multiple phase III catalysts, and profitability targeted by 2027 - TradingView
XOMA: Biotech royalty aggregator grew to 100+ assets, with strong cash flow and key 2026 milestones ahead - TradingView
XOMA Highlights Royalty Aggregation Strategy in Updated Presentation - TipRanks
XOMA (NASDAQ: XOMA) details 2025 royalty cash, buybacks and litigation costs - Stock Titan
(XOMAO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Liquidity Mapping Around (XOMA) Price Events - Stock Traders Daily
LVTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
XOMA Royalty Corporation (XOMA) Stock Analysis: Unveiling A 145.89% Potential Upside - DirectorsTalk Interviews
What Analysts Are Saying About XOMA Royalty Stock - Sahm
Leerink raises Xoma stock price target on royalty outlook - Investing.com
XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
XOMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MURAMural Oncology PLC Latest Stock News & Market Updates - Stock Titan
What drives XOMA Royalty Corporation’s stock price2025 Analyst Calls & Short-Term High Return Ideas - mfd.ru
Understanding the Setup: (XOMAP) and Scalable Risk - Stock Traders Daily
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right - Intellectia AI
XOMA Royalty Corporation (XOMA) Stock Analysis: Unlocking a Potential 164.89% Upside with Strategic Biotech Ventures - DirectorsTalk Interviews
XOMA Royalty to Present at Investor Conferences in March - The Globe and Mail
Biotech royalty player XOMA lines up March investor talks - Stock Titan
How (XOMAO) Movements Inform Risk Allocation Models - Stock Traders Daily
Why (XOMA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 27.4% - MarketBeat
Why analysts remain bullish on XOMA stockJuly 2025 Chart Watch & High Yield Stock Recommendations - mfd.ru
Why XOMA Royalty Corporation stock is rated strong buyJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru
TD Cowen Maintains XOMA Corp(XOMA.US) With Hold Rating - 富途牛牛
Xoma stock rating reinstated as Hold by TD Cowen after Generation Bio acquisition - Investing.com Australia
XOMA Royalty Corporation (XOMA): Investor Outlook with a Promising 177% Potential Upside - DirectorsTalk Interviews
Buyback Watch: What drives XOMA Royalty Corporations stock priceJuly 2025 Market Mood & Risk Controlled Stock Alerts - baoquankhu1.vn
Can XOMA Royalty Corporation maintain its current growth rateTrade Risk Report & Fast Entry and Exit Trade Plans - mfd.ru
Is XOMA Royalty Corporation forming a breakout pattern2025 Volatility Report & Free Expert Approved Momentum Trade Ideas - mfd.ru
XOMA Royalty’s Preferreds Still Offer Compelling Income Despite Call Risk (NASDAQ:XOMA) - Seeking Alpha
Growth Value: Can XOMA Royalty Corporation deliver alphaEarnings Risk Summary & Capital Efficient Trade Techniques - baoquankhu1.vn
Is XOMA Royalty Corporation's (NASDAQ:XOMA) 20% ROE Strong Compared To Its Industry? - simplywall.st
Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout - The Business Journals
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share - Investing.com Australia
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share By Investing.com - Investing.com South Africa
Street Watch: What is the next catalyst for XOMA Royalty CorporationJuly 2025 Macro Moves & Trade Opportunity Analysis - baoquankhu1.vn
XOMA Royalty completes acquisition of Generation Bio; GBIO delisted from Nasdaq - Investing.com
XOMA Completes Acquisition and Delisting of Generation Bio - TipRanks
XOMA Royalty Completes Generation Bio Acquisition and Merger - TipRanks
XOMA Royalty Corporation Completes Acquisition of Generation Bio Co. Through Tender Offer - Quiver Quantitative
Generation Bio investors cashed out at $4.2913 a share in XOMA takeover - Stock Titan
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. - Sahm
The Technical Signals Behind (XOMAP) That Institutions Follow - Stock Traders Daily
The Future of Kinnate Biopharma Now Rests with Contingent Value Rights - AD HOC NEWS
Hillevax Acquisition Finalized: Shareholder Payouts and Future Rights Explained - AD HOC NEWS
Published on: 2026-02-09 02:34:15 - baoquankhu1.vn
Movement Recap: Will XOMA Royalty Corporation outperform its industry peersWeekly Earnings Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Xoma Corporation Stock (XOMAO) Financials Data
There is no financial data for Xoma Corporation (XOMAO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.14%
0.19%
Cap:
|
Volume (24h):